In silico insights into design of novel VEGFR-2 inhibitors: SMILES-based QSAR modelling, and docking studies on substituted benzo-fused heteronuclear derivatives

References

• H.A. Mahdy, M.K. Ibrahim, A.M. Metwaly, A. Belal, A.B.M. Mehany, K.M.A. El-Gamal, A. El-Sharkawy, M.A. Elhendawy, M.M. Radwan, M.A. Elsohly, and I.H. Eissa, Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4 (3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducer, Bioorg. Chem. 94 (2020), pp. 103422. doi:10.1016/j.bioorg.2019.103422.
   PubMed Web of Science ®Google Scholar
• M. Shibuya, Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies, Genes Cancer 2 (2011), pp. 1097–1105. doi:10.1177/1947601911423031.
   PubMedGoogle Scholar
• X. Wang, A.M. Bove, G. Simone, and B. Ma, Molecular bases of VEGFR-2-mediated physiological function and pathological role, Front Cell Dev. Biol. 8 (2020). doi:10.3389/fcell.2020.599281.
   Web of Science ®Google Scholar
• S. Banerjee, S. Kejriwal, B. Ghosh, G. Lanka, T. Jha, and N. Adhikari, Fragment-based investigation of thiourea derivatives as VEGFR-2 inhibitors: A cross-validated approach of ligand-based and structure-based molecular modelling studies, J. Biomol. Struct. Dyn. 42 (2024), pp. 1047–1063. doi:10.1080/07391102.2023.2198039.
   PubMed Web of Science ®Google Scholar
• T.A. Farghaly, W.A. Al-Hasani, and H.G. Abdulwahab, An updated patent review of VEGFR-2 inhibitors (2017-present), Expert Opin. Ther. Pat. 31 (2021), pp. 989–1007. doi:10.1080/13543776.2021.1935872.
   PubMed Web of Science ®Google Scholar
• S. Vishakha, K. Kajal, S. Mondal, S.K. Wahan, B.D. Kurmi, G.D. Gupta, and P. Patel, Novel VEGFR-2 kinase inhibitors as anticancer agents: A review focusing on SAR and molecular docking studies (2016–2021), Chem. Biodiv. 20 (2023), pp. e202200847. doi:10.1002/cbdv.202200847.
   PubMed Web of Science ®Google Scholar
• X. Yuan, Q. Yang, T. Liu, K. Li, Y. Liu, C. Zhu, Z. Zhang, L. Li, C. Zhang, M. Xie, J. Lin, J. Zhang, and Y. Jin, Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 Kinase, Eur. J. Med. Chem. 179 (2019), pp. 147–165. doi:10.1016/j.ejmech.2019.06.054.
   PubMed Web of Science ®Google Scholar
• A.A. El-Helby, H. Sakr, I.H. Eissa, A.A. Al-Karmalawy, and K. El-Adl, Benzoxazole/benzothiazole‐derived VEGFR‐2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations, Arch. Pharm. 352 (2019), pp. 1900178. doi:10.1002/ardp.201900178.
   Web of Science ®Google Scholar
• C. Porta, P. Giglione, W. Liguigli, and C. Paglino, Dovitinib (CHIR258, TKI258): Structure, development and preclinical and clinical activity, Future Oncol. 11 (2015), pp. 39–50. doi:10.2217/fon.14.208.
   PubMed Web of Science ®Google Scholar
• Y. Jiang, W. Yang, F. Wang, and B. Zhou, In silico studies of a novel scaffold of benzoxazole derivatives as anticancer agents by 3D-QSAR, molecular docking and molecular dynamics simulations, R. Soc. Chem. 13 (2023), pp. 14808–14824. doi:10.1039/D3RA01316B.
   Google Scholar
• J.B. Tong, Y. Feng, D. Luo, and T.H. Wang, 6‑amide‑2‑aryl benzoxazole/benzimidazole derivatives as VEFGR‑2 inhibitors in two‑and three‑dimensional QSAR studies: Topomer CoMFA and HQSAR, Chem. Pap. 75 (2021), pp. 3551–3562. doi:10.1007/s11696-021-01588-w.
   Web of Science ®Google Scholar
• E.A.A. El-Meguid, A.M. Naglah, G.O. Moustafa, H.M. Award, and A.M. El Kerdawy, Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies, Bioor. Med. Chem. Lett. 58 (2022), pp. 128529. doi:10.1016/j.bmcl.2022.128529.
   PubMed Web of Science ®Google Scholar
• A.A. Toropov and A.P. Toropova, The Monte Carlo method as a tool to build up predictive QSPR/QSAR, Curr. Comput. Aided Drug Des. 15 (2019), pp. 197–206. doi:10.2174/1573409915666190328123112.
   Google Scholar
• A.P. Toropova and A.A. Toropov, CORAL software: Prediction of carcinogenicity of drugs by means of the Monte Carlo method, Eur. J. Pharm. Sci. 52 (2014), pp. 21–25. doi:10.1016/j.ejps.2013.10.005.
   PubMed Web of Science ®Google Scholar
• A.A. Toropov, I. Raska Jr, A.P. Toropova, M. Raskova, A.M. Veselinovic, and J.B. Veselinovic, The study of the index of ideality of correlation as a new criterion of predictive potential of QSPR/QSAR-models, Sci. Total Environ. 659 (2019), pp. 1387–1394. doi:10.1016/j.scitotenv.2018.12.439.
   PubMed Web of Science ®Google Scholar
• M. Hasegawa, N. Nishigaki, Y. Washio, K. Kano, P.A. Harris, H. Sato, I. Mori, R.I. West, M. Shibahara, H. Toyoda, L. Wang, R.T. Nolte, J.M. Veal, and M. Cheung, Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors, J. Med. Chem. 50 (2007), pp. 4453–4470. doi:10.1021/jm0611051.
   PubMed Web of Science ®Google Scholar
• L. Shi, T. Wu, Z. Wang, J. Xue, and Y. Xu, Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors, Eur. J. Med. Chem. 84 (2014), pp. 698–707. doi:10.1016/j.ejmech.2014.07.071.
   PubMed Web of Science ®Google Scholar
• A.S. Mostafa, R.M. Gomaa, and M.A. Elmorsy, Design and synthesis of 2-phenyl benzimidazole derivatives as VEGFR-2 inhibitors with anti-breast cancer activity, Chem. Biol. Drug. Des. 93 (2019), pp. 454–463. doi:10.1111/cbdd.13433.
   PubMed Web of Science ®Google Scholar
• M.A. Abdullaziz, H.T. Abdel-Mohsen, A.M. El Kerdawy, F.A.F. Ragab, M.M. Ali, S.M. Abu-Bakr, A.S. Girgis, and H.I. El Diwani, Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors, Eur. J. Med. Chem. 136 (2017), pp. 315–329. doi:10.1016/j.ejmech.2017.04.068.
   PubMed Web of Science ®Google Scholar
• V.G. Reddy, T.S. Reddy, C. Jadala, M.S. Reddy, F. Sultana, R. Akunuri, S.K. Bhargava, D. Wlodkowic, P. Srihari, and A. Kamal, Pyrazolo-benzothiazole hybrids: synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model, Eur. J. Med. Chem. 182 (2019), pp. 111609. doi:10.1016/j.ejmech.2019.111609.
   PubMed Web of Science ®Google Scholar
• M. Zi, F. Liu, D. Wu, K. Li, D. Zhang, C. Zhu, Z. Zhang, L. Li, C. Zhang, M. Xie, J. Lin, J. Zhang, and Y. Jin, Discovery of 6-arylurea-2-arylbenzoxazole and 6-arylurea-2-arylbenzimidazole derivatives as angiogenesis inhibitors: Design, synthesis and in vitro biological evaluation, Chem. Med. Chem. 14 (2019), pp. 1291–1302. doi:10.1002/cmdc.201900216.
   Google Scholar
• H.T. Abdel‐Mohsen, E.A.A. El‐Meguid, A.M. El Kerdawy, A.E.E. Mahmoud, and M.M. Ali, Design, synthesis, and molecular docking of novel 2‐arylbenzothiazole multi angiokinase inhibitors targeting breast cancer, Arch. Pharm. 353 (2020), pp. 1900340. doi:10.1002/ardp.201900340.
   PubMed Web of Science ®Google Scholar
• A.A. El-Helby, H. Sakr, I.H. Eissa, H. Abulkhair, A.A. Al-Karmalawy, and K. El-Adl, Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR‐2 inhibitors, Arch. Pharm. 352 (2019), pp. 1900113. doi:10.1002/ardp.201900113.
   Web of Science ®Google Scholar
• M.S. Taghour, H.A. Mahdy, M.H. Gomaa, A. Aglan, M.G. Eldeib, A. Elwan, M.A. Dahab, E.B. Elkaeed, A.A. Alsfouk, M.M. Khalifa, I.H. Eissa, and H. Elkady, Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and antiproliferative evaluation, J. Enz. Inhib. Med. Chem. 37 (2022), pp. 2063–2077. doi:10.1080/14756366.2022.2103552.
   PubMed Web of Science ®Google Scholar
• I.H. Eissa, R. El-Haggar, M.A. Dahab, M.F. Ahmed, H.A. Mahdy, R.I. Alsantali, A. Elwan, N. Masurier, and S.S. Fatahala, Design, synthesis, molecular modelling and biological evaluation of novel benzoxazole-benzamide conjugates via a 2-thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers, J. Enz. Inhib. Med. Chem. 37 (2022), pp. 1587–1599. doi:10.1080/14756366.2022.2081844.
   PubMed Web of Science ®Google Scholar
• M.M. Al-Sanea, A. Hamdi, A.A.B. Mohamed, H.W. El-Shafey, M. Moustafa, A.A. Elgazar, W.M. Eldehna, H.U. Rahman, D.G.T. Parambi, R.M. Elbargisy, S. Selim, S.N.A. Bukhari, O.M. Hendawy, and S.S. Tawfik, New benzothiazole hybrids as potential VEGFR-2 inhibitors: Design, synthesis, anticancer evaluation, and in silico study, J. Enzy. Inhib. Med. Chem. 38 (2023), pp. 2166036. doi:10.1080/14756366.2023.2166036.
   PubMed Web of Science ®Google Scholar
• N.M. O’Boyle, M. Banck, C.A. James, C. Morley, T. Vandermeersch, and G.R. Hutchison, Open babel: An open chemical toolbox, J. Cheminform. 3 (2011), pp. 1–14. doi:10.1186/1758-2946-3-33.
   PubMed Web of Science ®Google Scholar
• K. Bagri, A. Kapoor, P. Kumar, and A. Kumar, Hybrid descriptors–conjoint indices: A case study on imidazole-thiourea containing glutaminyl cyclase inhibitors for design of novel anti-Alzheimer’s candidates, SAR QSAR Environ. Res. 34 (2023), pp. 361–381. doi:10.1080/1062936X.2023.2212175.
   PubMed Web of Science ®Google Scholar
• A.A. Toropov, A.P. Toropova, S.E. Martyanov, E. Benfenati, G. Gini, D. Leszczynska, and J. Leszczynski, Comparison of SMILES and molecular graphs as the representation of the molecular structure for QSAR analysis for mutagenic potential of polyaromatic amines, Chemom. Intell. Lab. Sys. 109 (2011), pp. 94–100. doi:10.1016/j.chemolab.2011.07.008.
   Web of Science ®Google Scholar
• S. Ahmadi, S. Lotfi, S. Afshari, P. Kumar, and E. Ghasemi, CORAL: Monte Carlo based global QSAR modelling of bruton tyrosine kinase inhibitors using hybrid descriptors, SAR QSAR Environ. Res. 32 (2021), pp. 1013–1031. doi:10.1080/1062936X.2021.2003429.
   PubMed Web of Science ®Google Scholar
• D. Sokolovic, V. Stankovic, D. Toskic, L. Lilic, G. Rankovic, J. Rankovic, G. Nedin-Rankovic, and A.M. Veselinovic, Monte Carlo-based QSAR Modeling of dimeric pyridinium compounds and drug design of new potent acetylcholine esterase inhibitors for potential therapy of myasthenia gravis, Struct. Chem. 27 (2016), pp. 1511–1519. doi:10.1007/s11224-016-0776-z.
   Web of Science ®Google Scholar
• D. Weininger, SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules, J. Chem. Inj. Comput. Sci. 28 (1988), pp. 31–36. doi:10.1021/ci00057a005.
   Google Scholar
• A.A. Toropov, I. Gutmanb, and B. Furtula, Graph of atomic orbitals and the molecular structure-descriptors based on it, J. Serb. Chem. Soc. 70 (2005), pp. 669–674. doi:10.2298/JSC0504669T.
   Web of Science ®Google Scholar
• A.P. Toropova, A.A. Toropov, J.B. Veselinovi, F.N. Miljkovic, and A.M. Veselinovi, QSAR models for HEPT derivates as NNRTI inhibitors based on Monte Carlo method, Eur. J. Med. Chem. 77 (2014), pp. 298–305. doi:10.1016/j.ejmech.2014.03.013.
   PubMed Web of Science ®Google Scholar
• P. Gramatica, Principles of QSAR models validation: Internal and external, QSAR Comb. Sci. 26 (2007), pp. 694–701. doi:10.1002/qsar.200610151.
   Google Scholar
• S. Shayanfar and A. Shayanfar, Comparison of various methods for validity evaluation of QSAR models, BMC Chem. 16 (2022), pp. 63. doi:10.1186/s13065-022-00856-4.
   PubMed Web of Science ®Google Scholar
• A. Golbraikh and A. Tropsha, Beware of q2! J. Mol. Graph. Model 20 (2002), pp. 269–276. doi:10.1016/S1093-3263(01)00123-1.
   PubMed Web of Science ®Google Scholar
• A. Shayanfar and S. Shayanfar, Is regression through origin useful in external validation of QSAR models? Eur. J. Pharm. Sci. 59 (2014), pp. 31–35. doi:10.1016/j.ejps.2014.03.007.
   PubMed Web of Science ®Google Scholar
• P.K. Ojha, I. Mitra, R.N. Das, and K. Roy, Further exploring Rm2 metrics for validation of qspr models, Chemom. Intell. Lab. Syst. 107 (2011), pp. 194–205. doi:10.1016/j.chemolab.2011.03.011.
   Web of Science ®Google Scholar
• P.P. Roy and K. Roy, QSAR studies of CYP2D6 inhibitor aryloxypropanolamines using 2d and 3D descriptors, Chem. Biol. Drug. Des. 73 (2009), pp. 442–455. doi:10.1111/j.1747-0285.2009.00791.x.
   PubMed Web of Science ®Google Scholar
• N. Chirico and P. Gramatica, Real external predictivity of QSAR models: How to evaluate i? comparison of different validation criteria and proposal of using the concordance correlation coefficient, J. Chem. Inf. Model. 51 (2011), pp. 2320–2335. doi:10.1021/ci200211n.
   PubMed Web of Science ®Google Scholar
• P.K. Ojha and K. Roy, Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection, Chemom. Intell. Lab. Syst. 109 (2011), pp. 146–161. doi:10.1016/j.chemolab.2011.08.007.
   Web of Science ®Google Scholar
• T. Hanser, C. Barber, J.F. Marchaland, and S. Werner, Applicability domain: Towards a more formal definition, SAR QSAR Environ. Res. 27 (2016), pp. 865–881. doi:10.1080/1062936X.2016.1250229.
   PubMed Web of Science ®Google Scholar
• O. Trott and A.J. Olson, Autodock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem. 31 (2010), pp. 455–61. doi:10.1002/jcc.21334.
   PubMed Web of Science ®Google Scholar
• M. McTigue, B.W. Murray, J.H. Chen, Y.L. Deng, J. Solowiej, and R.S. Kania, Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors, Proc. Natl. Acad. Sci. USA 45 (2012), pp. 18281–18289. doi:10.1073/pnas.1207759109.
   Google Scholar
• K. Stierand and M. Rarey, Drawing the PDB: Protein-ligand complexes in two dimensions, ACS Med. Chem. Lett. 1 (2010), pp. 540–545. doi:10.1021/ml100164p.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2022−1. Desmond Molecular Dynamics System; D. E. Shaw Research, Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY, 2021.
   Google Scholar